LBP-1 (drug)
LBP-1 is a drug originally developed by Organon for the treatment of neuropathic pain, and subsequently further developed by Merck after they acquired Organon's patents following their merger with Schering-Plough. It acts as a potent and selective cannabinoid receptor agonist, with high potency at both the CB1 and CB2 receptors, but low penetration of the blood–brain barrier. This makes LBP-1 peripherally selective, and while it was effective in animal models of neuropathic pain and allodynia, it did not produce cannabinoid-appropriate responding suggestive of central effects, at any dose tested.
See also
References
Piper LBP
The Piper LBP was a glider bomb, or "Glomb", developed by Piper Aircraft for the United States Navy during World War II. Developed as one of three "Glomb" aircraft, the inherent limitations of the Glomb and the technology of the time, combined with difficulties encountered in testing of the prototype, led to the production contract for the LBP-1 being reduced, then cancelled, with none of the Glomb aircraft ever seeing operational service.
Design and development
During late 1940, a proposal was made to the United States Navy outlining a concept called "Glomb", for "glider bomb". The Glomb concept called for the construction of inexpensive gliders, that would be remotely controlled from another aircraft, to carry bombs to a target, thus reducing the risk to aircrew. Glomb was intended to be towed by an ordinary carrier-based aircraft to the area of the target, where it would be released; guidance following release would be provided via a TV camera located in the nose of the glider, which would transmit its signal to a piloted aircraft, an operator then using radio control to steer the Glomb to its target. Following consideration the Glomb concept was deemed to be potentially feasible, the project was given official status by the Bureau of Aeronautics in the April 1941.
Podcasts:
